Xarxa de sensors sense fils per a la monitorització ambiental del Campus del Baix Llobregat

REALnet és una xarxa de sensors sense fils per la monitorització ambiental del Campus del Baix Llobregat de la UPC. En la comunicació s’usa l’especificació Zigbee. El treball parteix d’un desplegament inicial format per un node sensor, que mesura el nivell i temperatura de l’estany del Campus, un node encaminador, que retransmet les dades de forma transparent, i un node coordinador, que rep les dades del node sensor i les processa. La comunicació entre els nodes no era prou robusta degut a la presència d’edificis i estructures presents desprès del desplegament inicial de la xarxa. Aquest treball proposa i implementa un nou desplegament a fi de millorar la qualitat de l’enllaç i que té en compte la cobertura de l’enllaç radio i la presència d’edificacions futures. A tal fi, s’afegeixen dos nous nodes encaminadors. Els nodes encaminadors estan permanentment activats i s’alimenten a partir de pannells solars. Amb la configuració actual el node sensor envia dades amb una baixa cadència (cada 2 hores). A fi de reduir el consum i per tant les dimensions del pannell solar dels nodes encaminadors es dissenya i implementa també un nou node que s’activa només per oferir l’enllaç del node sensor amb el node coordinador. Es mostren mesures de camp que validen el correcte funcionament de la xarxa i en particular del nou node encaminador, capaç d’entrar en mode de consum reduït

Estudio de la intercara en materiales compuestos tipo cermet para el diseño de matrices metálicas alternativas

La ponencia presentada en: XI Congreso Nacional de Materiales Compuestos, celebrado los días 6, 7 y 8 de julio de 2015, en Móstoles (España).Uno de los grandes temas de investigación actual en el campo de los materiales compuestos tipo cermet base TiCN es la búsqueda de matrices metálicas alternativas a las convencionales las cuales cuentan en su composición Ni y/o Co de manera mayoritaria. El objetivo principal que debe cumplir el cermet con una matriz metálica alternativa es alcanzar propiedades similares e incluso superiores a las obtenidas con matrices convencionales utilizando materiales más económicos e inocuos. Además, siendo un material compuesto, a la hora de diseñar la composición de una nueva matriz metálica se debe tener en cuenta cómo es su interacción con el refuerzo cerámico. Este concepto cobra una mayor importancia en este tipo de materiales debido a que su fabricación se lleva a cabo mediante sinterización en fase líquida y las propiedades finales del material compuesto dependerán de la mojabilidad y solubilidad entre ambas fases. Algunas investigaciones sobre cermets reforzados con partículas de TiCN y matriz convencional han concluido que carburos como WC ó Mo2C tienen una gran influencia en la sinterabilidad de estos materiales compuestos porque mejoran la mojabilidad de la matriz metálica sobre el refuerzo cerámico. El objetivo principal de este trabajo es el estudio sistemático de la influencia de estos carburos en la sinterabilidad de un cermet base TiCN con Fe como matriz metálica. Para ello se ha estudiado la solubilidad entre ambas fases estudiando su intercara tanto de forma experimental como mediante herramientas de simulación termodinámica y cinética utilizando el software Dictra. Gracias a los resultados obtenidos se crea una metodología de trabajo que permite conocer la influencia de la composición en la solubilidad entre las dos fases siendo una herramienta útil en el diseño de nuevas matrices metálicas alternativas en cermets.Los autores agradecen la financiación recibida para la realización de este trabajo al MINECO (proyecto MAT2012-38650-C02-01) y a la Comunidad de Madrid por el programa MULTIMAT-CHALLENGE, ref. S2013/MIT-2862.Publicad

Critical agitation for microcarrier suspension in orbital shaken bioreactors : Experimental study and dimensional analysis

Orbital shaken bioreactors are widely used at the laboratory scale for the culture of animal cells in suspension mode. In the case of adherent-dependent cell lines,the choice of agitation conditions at which all particles are just-suspended (or attain complete suspension) has often to be determined.Indeed, with orbital shaken bioreactors,this choice results from the combination of two parameters : the orbital diameter and the agitation rate. That is why an experimental protocol for the determination of critical agitation conditions for microcarrier complete suspension has been developed in this paper.It consisted in a side-view visualization of blue-stained particles in shaken Erlenmeyer flasks and cylindrical flasks. 220 experiments representative of animal cell culture conditions have been carried out to study the effect of various operating conditions (bioreactor size and geometry, particle type, density and diameter,liquid viscosity, shaking diameter, filling ratio). Furthermore, a dimensional analysis has been performed, leading to a correlation relating a Froude number (in which the critical agitation Nc for complete particle suspension is sembedded) to four other dimensionless numbers. Then,the critical agitation conditions determined in this paper were analyzed and discussed with respect to the data available in the literature on the flow structure occurring inside the flask.Our findings revealed that high orbital shaking diameters and large cylindrical vessels should be promoted to get microcarriers into suspension at a minimized power dissipation per unit of volume

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

PURPOSE: Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR) gene alterations, including BRCA1/2 alterations, can sensitize cancer cells to poly (ADP-ribose) polymerase inhibition, which may improve outcomes in treatment-naïve mCRPC when combined with androgen receptor signaling inhibition. METHODS: MAGNITUDE (ClinicalTrials.gov identifier: NCT03748641) is a phase III, randomized, double-blinded study that evaluates niraparib and abiraterone acetate plus prednisone (niraparib + AAP) in patients with (HRR+, n = 423) or without (HRR-, n = 247) HRR-associated gene alterations, as prospectively determined by tissue/plasma-based assays. Patients were assigned 1:1 to receive niraparib + AAP or placebo + AAP. The primary end point, radiographic progression-free survival (rPFS) assessed by central review, was evaluated first in the BRCA1/2 subgroup and then in the full HRR+ cohort, with secondary end points analyzed for the full HRR+ cohort if rPFS was statistically significant. A futility analysis was preplanned in the HRR- cohort. RESULTS: Median rPFS in the BRCA1/2 subgroup was significantly longer in the niraparib + AAP group compared with the placebo + AAP group (16.6 v 10.9 months; hazard ratio [HR], 0.53; 95% CI, 0.36 to 0.79; P = .001). In the overall HRR+ cohort, rPFS was significantly longer in the niraparib + AAP group compared with the placebo + AAP group (16.5 v 13.7 months; HR, 0.73; 95% CI, 0.56 to 0.96; P = .022). These findings were supported by improvement in the secondary end points of time to symptomatic progression and time to initiation of cytotoxic chemotherapy. In the HRR- cohort, futility was declared per the prespecified criteria. Treatment with niraparib + AAP was tolerable, with anemia and hypertension as the most reported grade ≥ 3 adverse events. CONCLUSION: Combination treatment with niraparib + AAP significantly lengthened rPFS in patients with HRR+ mCRPC compared with standard-of-care AAP

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

PURPOSE: KRAS is the most commonly mutated oncogene in human tumors. KRAS-mutant cells may exhibit resistance to the allosteric MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) and allosteric AKT inhibitors (such as MK-2206), the combination of which may overcome resistance to both monotherapies. EXPERIMENTAL DESIGN: We conducted a dose/schedule-finding study evaluating MK-2206 and selumetinib in patients with advanced treatment-refractory solid tumors. Recommended dosing schedules were defined as MK-2206 at 135 mg weekly and selumetinib at 100 mg once daily. RESULTS: Grade 3 rash was the most common dose-limiting toxicity (DLT); other DLTs included grade 4 lipase increase, grade 3 stomatitis, diarrhea, and fatigue, and grade 3 and grade 2 retinal pigment epithelium detachment. There were no meaningful pharmacokinetic drug-drug interactions. Clinical antitumor activity included RECIST 1.0-confirmed partial responses in non-small cell lung cancer and low-grade ovarian carcinoma. CONCLUSION: Responses in KRAS-mutant cancers were generally durable. Clinical cotargeting of MEK and AKT signaling may be an important therapeutic strategy in KRAS-driven human malignancies (Trial NCT number NCT01021748).The Drug Development Unit of the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research is supported in part by a programme grant from Cancer Research UK (grant number: C347/A18077). Support was also provided by an Experimental Cancer Medicine Centre grant (no grant number) and the National Institute for Health Research Biomedical Research Centre (jointly to the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research) (grant numbers: A46/CCR - CCR4057 & CCR4058).This is the accepted manuscript of a paper published in Clinical Cancer Research, February 15, 2015 21; 739, doi: 10.1158/1078-0432.CCR-14-190